Skip to content

The Volumetric Analysis of Fat Grafting

The Volumetric Analysis of Fat Grafting for Aesthetic Body Contouring

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03544593
Enrollment
50
Registered
2018-06-04
Start date
2018-01-04
Completion date
2019-03-31
Last updated
2018-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autologous Fat Grafting

Brief summary

Title: The Volumetric Analysis of Fat Grafting for Aesthetic Body Contouring. Subjects who wish to undergo fat grafting for aesthetic body contouring will be offered enrollment to the study. The study will consist of a Screening/Baseline visit, Surgery day and 3 follow up visits. Each follow up visit will utilize Vectra 3D photography (Canfeild, NJ) to collect volumetric data. At the conclusion of the study, Volume data from Baseline and 3 follow up visits will be analyzed to determine fat retention rates.

Interventions

DEVICERevolve System

Fat grafting system

Sponsors

Allergan
CollaboratorINDUSTRY
Hunstad Kortesis Bharti Cosmetic Sugrery
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Females or Males in good general health age 18 - 65 years of age 2. Must be willing to give and sign a HIPAA form and informed consent form 3. Must be willing and able to comply with all study protocols and schedules 4. Negative urine pregnancy test prior to surgery treatment (if applicable) 5. The patient must have had a stable weight (no fluctuation of \>15 pounds in a year), diet, and physical activity for the previous 6 months

Exclusion criteria

1. Pregnancy, currently breast feeding or planning pregnancy for the duration of the trial 2. History of breast cancer if fat grafting to breasts 3. Patients who smoke or use nicotine products 4. Any UNCONTROLLED systemic disease -a potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study 5. Diabetes Mellitus 6. Subject has a clinically significant coagulation disorder or disease, defined as a platelet count \< 100,000 per microliter or International Normalized Ratio \> 1.5 within 4 weeks of surgery 7. Patients under the age of 18 8. Patients undergoing fat grafting but refuse enrollment 9. Patients with an active infection 10. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.

Design outcomes

Primary

MeasureTime frameDescription
Graft retention9 monthsVectra 3D volumetric analysis will be utilized to evaluate graft retention.

Secondary

MeasureTime frame
Volume of adipose harvested (mL)Intra Op
Volume of adipocyte injected (mL)Intra Op
Operating room time (harvesting, processing, and reinjection time) (min)Intra Op
Standardized before and after photosPre op, 3 months, 6 months, 9 months

Countries

United States

Contacts

Primary ContactKelly Costin, RN, BSN
kelly.c@hkbsurgery.com7046599000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026